American Association of Individual Investors

Why Replimune Group, Inc.’s (REPL) Stock Is Down 7.58%

As of Friday, March 13, Replimune Group, Inc.’s REPL share price has dipped by 7.58%, which has investors questioning if this ...
Nasdaq

REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings

REPLIMUNE GROUP ($REPL) posted quarterly earnings results on Thursday, May 22nd. The company reported earnings of -$0.82 per share, missing estimates of -$0.77 by $0. ...
Nasdaq

Replimune Group Inc. Stock (REPL) Opinions on FDA Drug Rejection

Recent discussions on X about Replimune Group Inc. (REPL) have been ignited by the U.S. FDA's rejection of the company's lead drug, RP1, for melanoma treatment in combination therapy. Many users are ...
Seeking Alpha

Replimune: Continuing To Justify The Bear Thesis (For Now)

Replimune Group, Inc.'s stock has fallen 35% in 2024, and an inflection point is not expected yet. The company is working on RP1, an oncolytic virus therapy, and has shared positive results from their ...
Hosted on MSN

Replimune Stock Plunged 42% Today – Here’s Why

Replimune Group, Inc. (REPL) announced on Thursday that a path forward for approval of its lead candidate for the treatment of advanced melanoma has not been determined, despite a meeting with the U.S ...